Combination of a haploidentical SCT with an unrelated cord blood unit: a single-arm prospective study

摘要: We conducted a single-arm prospective study in 50 patients who received the combination of an haploidentical stem cell graft and unrelated umbilical cord blood unit for treatment hematological malignancies. The median time neutrophil engraftment was 13 days (11–20 days), platelets 15 (11–180 days). All surviving attained complete except three presented mixed with increasing decreasing haplo mismatch chimerism during first 4 months after transplantation. cumulative incidence grade II–IV acute GVHD 20%±0.327% at day+100, chronic 19.26%±1.0% 1 year. 1-year relapse 19.78%±1%, TRM 16.2%±0.54%. At year, overall survival 78.6%±7.6% PFS 64.0%±11.0%. BU/CY-based conditional regimen showed significant superiority over TBI/CY on (relative risk=5.012, 95% confidence interval, 1.146–21.927, P=0.032). In conclusion, co-infusion may potentially improve outcome allogeneic hematopoietic SCT.